Stocktoria
RELMADA THERAPEUTICS, INC. RLMD
RELMADA THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $26.9M | $46.2M | $54.8M | $113.3M | $90.6M | $36.0M | $7.9M | $7.0M | $2.9M | $1.3M |
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M | -$60.8M | -$15.1M | -$12.7M | -$6.9M | -$7.2M |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M | -$125.8M | -$59.5M | -$15.0M | -$17.3M | -$9.0M | -$6.3M |
| EPS (diluted) | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 | — | — | — | — | — |
| Operating cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M | -$27.8M | -$12.1M | -$10.5M | -$6.0M | -$6.5M |
| Cash & equivalents | $3.5M | $3.9M | $4.1M | $5.4M | $44.4M | $2.5M | $36.3M | $9.2M | $2.2M | $1.7M |
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M | $118.2M | $117.1M | $10.2M | $3.0M | $2.8M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M | $12.6M | $1.5M | $2.6M | $8.6M | $1.4M |
| Shareholders' equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M | $105.6M | $115.7M | $7.6M | -$5.5M | $1.5M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.